Eosinophilic Esophagitis
Conditions
Keywords
Esophagitis, Eosinophilic Esophagitis, Esophageal Diseases, Gastrointestinal Diseases, Digestive System Diseases
Brief summary
Purpose: To validate our previously developed model of risk factors for diagnosis of eosinophilic esophagitis (EoE), and to assess the utility of serum levels of biomarkers in diagnosis and monitoring of treatment of EoE. Participants: Up to a total of 800 participants (approximately 400 with EoE and 400 without EoE) who are referred for upper endoscopy. Procedures: This is a prospective cohort study. Patients will be compared with newly diagnosed EoE to non-EoE controls, obtain baseline measures, reassess EoE patients after treatment, and also reassess untreated controls. Data collection will include questionnaire results, blood collection, and tissue collection (esophageal biopsies performed during upper endoscopy per pre-specified protocol). Blood will be analyzed for the presence of the candidate biomarkers. Patients will be compared with newly diagnosed EoE to non-EoE controls, obtain baseline measures, reassess EoE patients after treatment, and also reassess untreated controls. Data collection will include questionnaire results, blood collection, possible saliva collection, possible urine collection, and tissue collection (esophageal biopsies performed during upper endoscopy per pre-specified protocol). Blood will be analyzed for the presence of the candidate biomarkers, including eotaxin-3 and IL-13.
Interventions
OTHERSpecimen Collection
Blood collection, possible saliva collection, possible urine collection, and biopsy collection
OTHERQuestionnaires
Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
Sponsors
University of North Carolina, Chapel Hill
National Institutes of Health (NIH)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Referral for upper endoscopy (esophagogastroduodenoscopy; EGD) to evaluate specific symptoms (dysphagia, heartburn, reflux, chest pain, regurgitation, abdominal pain, nausea, or vomiting). 2. Age 18 or older
Exclusion criteria
1. Acute GI bleeding. 2. Known cancer of the esophagus, stomach, or small bowel. 3. Prior esophageal resection. 4. Esophageal varices. 5. Active anticoagulation or bleeding diathesis. 6. Medical instability (determined by the performing endoscopist) to precludes performing EGD. 7. Pregnancy 8. Inability to read or understand the consent form and questionnaire.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Risk factors in EoE diagnosis | Enrollment (day 1) | To validate our model of clinical, endoscopic, and histopathologic risk factors for diagnosis of EoE by calculating the EoE risk score which includes subject's age, allergic conditions, endoscopic findings, and eosinophil count. Subject's EoE risk scores will be compared between EoE patients and two non-EoE control groups: patients with dysphagia and patients with gastroesophageal reflux disease (GERD) who are not responsive to proton pump inhibitor (PPI) therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory serum biomarker measures | Enrollment (day 1) | To assess operating characteristics of serum biomarkers eotaxin-3 and IL-13 for diagnosis of incident cases of EoE as compared with two non-EoE control groups: patients with dysphagia and patients with GERD who are not responsive to PPI therapy. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATOREvan S Dellon, MD, MPH
University of North Carolina, Chapel Hill
Outcome results
None listed